Transfer pricing focus for value chain management in pharmaceutical and medical device companies

Transfer pricing focus for value chain management...

China Tax for Healthcare & Life Sciences Industry - Issue 2, March 2014  

1000

Related content

China Tax for Healthcare & Life Sciences Industry

Transfer pricing is in the spotlight for our second issue of the China Tax for the Healthcare and Life Sciences Industry series.   We have outlined the specific concerns of pharmaceutical and medical device companies operating in China regarding their transfer pricing arrangements, as well as our key recommendations for:   

  • Effectively managing the transfer pricing value chain in China;
  • Striking a sensible balance amongst the various regulatory authorities governing China’s healthcare companies regarding intercompany arrangements;
  • and Developing a feasible approach to mitigate detection and technical risk.

© 2022 KPMG Huazhen LLP, a People's Republic of China partnership, KPMG Advisory (China) Limited, a limited liability company in Mainland China, KPMG, a Macau (SAR) partnership, and KPMG, a Hong Kong (SAR) partnership, are member firms of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organisation.

For more detail about the structure of the KPMG global organisation please visit https://home.kpmg/governance.

京ICP备12028186号-1
京公网安备11010102003233号

Connect with us